Efficacy Evaluation of TheraSphere to Treat Inoperable Liver Cancer With Blockage of the Portal Vein
Status:
Terminated
Trial end date:
2017-05-23
Target enrollment:
Participant gender:
Summary
This is a two-arm, open-label, prospective, multi-center, randomized, active-controlled
clinical trial to assess efficacy and safety of TheraSphere in comparison to standard of care
therapy (sorafenib) in the treatment of participants with inoperable liver cancer and
blockage of the portal vein.
Phase:
Phase 3
Details
Lead Sponsor:
Boston Scientific Corporation BTG International Inc.